197TiP A randomized, double-blind, phase III study of pembrolizumab plus chemotherapy as first-line therapy in patients with HER2-negative, advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: KEYNOTE-859
Sign Up to like & getrecommendations! Published in 2020 at "Annals of Oncology"
DOI: 10.1016/j.annonc.2020.10.461
Abstract: s Annals of Oncology continue per protocol. Treatment with pembrolizumab/placebo will continue for up to 35 administrations (w2 years) or until disease progression, unacceptable toxicity, intercurrent illness that prevents further administration of treatment, or noncompliance.… read more here.
Keywords: bayer; merck; study; advisory consultancy ... See more keywords
A cross‐sectional study of psoriasis triggers among different ethno‐racial groups
Sign Up to like & getrecommendations! Published in 2017 at "Journal of the American Academy of Dermatology"
DOI: 10.1016/j.jaad.2017.04.1109
Abstract: Dr Bissonnette has received grants and research support, served as a consultant or received honoria from AbbVie, Amgen, Apopharma, Boehringer Ingelheim, Celgene, Dermira, Eli Lilly, Galderma, GSK-Stiefel, Merck, Incyte, Janssen, Kineta, Leo Pharma, Merck, Novartis,… read more here.
Keywords: leo pharma; eli lilly; celgene; merck ... See more keywords
KEYLYNK-010: Phase III study of pembrolizumab (pembro) plus olaparib (OLA) vs enzalutamide (ENZA) or abiraterone (ABI) in ENZA- or ABI-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who had progression on chemotherapy (CTx)
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz248.050
Abstract: Abstract Background In mCRPC pts unselected for homologous recombination deficiency (HRD), promising activity was seen with combination programmed death 1 inhibitor pembro and OLA in the phase 1b/2 KEYNOTE-365 study (NCT02861573), warranting further investigation in… read more here.
Keywords: abi enza; enza; pembro; genetics ... See more keywords
Pembrolizumab (pembro) plus lenvatinib (len) for first-line treatment of patients (pts) with advanced melanoma: Phase III LEAP-003 study
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz255.063
Abstract: Abstract Background Pembro, a PD-1 inhibitor, has shown effective antitumor activity, durable responses, and survival benefit in pts with advanced melanoma. Len—a potent inhibitor of VEGF receptors 1-3, FGF receptors 1-4, PDGF receptor α, RET,… read more here.
Keywords: pembro; advisory consultancy; merck; novartis ... See more keywords
166. A Phase 2b/3 Study to Evaluate the Efficacy and Safety of an Investigational Respiratory Syncytial Virus (RSV) Antibody, Clesrovimab, in Healthy Preterm and Full-Term Infants
Sign Up to like & getrecommendations! Published in 2025 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofae631.003
Abstract: Abstract Background Clesrovimab is an investigational, long-acting monoclonal antibody (mAb) targeting site IV of the fusion protein for the prevention of RSV lower respiratory tract infection in infants. Methods This phase 2b/3 double-blind, randomized, placebo-controlled… read more here.
Keywords: rahway usa; merck; merck inc; merck sharp ... See more keywords
P-1196. Drug-Drug Interactions (DDIs) With Letermovir (LET) for Cytomegalovirus (CMV) Prophylaxis in Pediatric (Birth to < 18 years of age) Hematopoietic Cell Transplant (HCT) Recipients
Sign Up to like & getrecommendations! Published in 2025 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofae631.1380
Abstract: Abstract Background HCT recipients receive multiple medications post-transplant, increasing the potential for DDIs. LET, a CMV terminase complex inhibitor approved for CMV prophylaxis in adult CMV-seropositive allogeneic HCT recipients, has the potential for DDIs with… read more here.
Keywords: merck; hct; research; let ... See more keywords
P-1499. Patient Characteristics and Clinical Outcomes Associated with Meropenem/Vaborbactam Treatment in Carbapenem-Resistant Enterobacterales Pneumonia
Sign Up to like & getrecommendations! Published in 2025 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofae631.1668
Abstract: Abstract Background Carbapenem-resistant Enterobacterales (CRE) are a major public health threat due to increasing prevalence and limited effective treatment options. Meropenem/vaborbactam (M/V) is a beta-lactam/beta-lactamase inhibitor agent designed to treat CRE. There is a paucity… read more here.
Keywords: treatment; merck; culture; meropenem vaborbactam ... See more keywords
518. Newborn immune transcriptome changes rapidly and is shaped by maternal SARS-CoV-2 infection and/or vaccination
Sign Up to like & getrecommendations! Published in 2025 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofae631.170
Abstract: Abstract Background SARS-CoV-2 infection during pregnancy is associated with adverse maternal effects, but its impact on infant’s immune development is not well defined. Using transcriptional profiles we analyzed the impact of SARS-CoV2 infection and/or vaccination… read more here.
Keywords: sars cov; infection vaccination; cov infection; merck ... See more keywords
P-609. Assessment of Parents’ Awareness and Attitudes towards Respiratory Syncytial Virus and its Prevention in the US
Sign Up to like & getrecommendations! Published in 2025 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofae631.807
Abstract: Abstract Background To assess the awareness and attitudes of parents towards respiratory syncytial virus (RSV) infection in the United States. Methods We developed an online, quantitative survey consisting of 34 questions, informed by a literature… read more here.
Keywords: respiratory syncytial; awareness attitudes; merck; prevention ... See more keywords
P-627. Modeling the Clinical and Economic Impact of Increasing Varicella Vaccination Coverage in Panama
Sign Up to like & getrecommendations! Published in 2025 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofae631.825
Abstract: Abstract Background Panama implemented two-dose universal varicella vaccination (UVV) in 2018. First-dose vaccination coverage rates (VCRs) declined from 91% (2018) to 70% (2021) during the COVID-19 pandemic. We quantified the clinical and economic impact of… read more here.
Keywords: impact increasing; merck; strategy; merck inc ... See more keywords
Immunogenicity of Inactivated Varicella Zoster Vaccine (ZVIN) in Autologous Hematopoietic Stem Cell Transplant (auto-HSCT) Recipients
Sign Up to like & getrecommendations! Published in 2017 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofx162.141
Abstract: Abstract Background Recipients of auto-HSCT have an increased risk of herpes zoster (HZ) infection; however, live attenuated varicella-zoster virus (VZV) vaccine is contraindicated in these patients. In this pivotal Phase III study (V212-001; NCT01229267) inactivated… read more here.
Keywords: merck; vaccine; auto hsct; placebo ... See more keywords